Abstract
Nanocarriers have been developed in order to protect drugs or to improve drugs efficiency by reaching the damaged tissue and avoiding systemic and local toxicity. By using HSP90 inhibitors, some cancer drug resistances have been overcome and the loading into nanocarriers of such drugs has shown an increase of their activities. This review will present some advantages of HSP90 inhibitors to treat resistant tumors; especially those targeting the mitochondrial protein TRAP1. We will also focus on the targeting of the primary tumors, cancer stem cells and metastatic cells.
| Original language | English |
|---|---|
| Pages (from-to) | 381-398 |
| Number of pages | 18 |
| Journal | Cancer Drug Resistance |
| Volume | 2 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1 Jan 2019 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cancer
- Heat-shock proteins
- Nanoparticles
- Resistance
Fingerprint
Dive into the research topics of 'Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver